Ionis Pharmaceuticals Inc (NASDAQ:IONS) has earned a consensus rating of “Hold” from the twelve brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, eight have given a hold rating and two have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $68.67.

A number of research firms have recently weighed in on IONS. TheStreet lowered Ionis Pharmaceuticals from a “b-” rating to a “c” rating in a report on Thursday, August 8th. Sanford C. Bernstein upgraded Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $80.00 target price on the stock in a report on Tuesday. Zacks Investment Research lowered Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, July 31st. Piper Jaffray Companies set a $75.00 target price on Ionis Pharmaceuticals and gave the company a “hold” rating in a report on Friday, May 24th. Finally, Evercore ISI set a $76.00 target price on Ionis Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday, August 7th.

NASDAQ:IONS traded up $2.05 on Friday, hitting $66.88. The stock had a trading volume of 1,438,586 shares, compared to its average volume of 1,176,234. The business’s fifty day moving average is $65.56 and its 200 day moving average is $69.43. The company has a market cap of $9.11 billion, a PE ratio of 22.59 and a beta of 1.97. The company has a quick ratio of 9.93, a current ratio of 10.01 and a debt-to-equity ratio of 0.45. Ionis Pharmaceuticals has a 52 week low of $43.27 and a 52 week high of $86.58.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.26. The business had revenue of $164.00 million for the quarter, compared to analyst estimates of $145.31 million. Ionis Pharmaceuticals had a return on equity of 38.70% and a net margin of 49.90%. The company’s quarterly revenue was up 39.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.29) earnings per share. Equities analysts predict that Ionis Pharmaceuticals will post -0.07 earnings per share for the current fiscal year.

In related news, Director Spencer R. Berthelsen sold 15,000 shares of the stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $63.67, for a total transaction of $955,050.00. Following the completion of the sale, the director now directly owns 99,404 shares of the company’s stock, valued at $6,329,052.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Stanley T. Crooke sold 22,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $71.52, for a total value of $1,573,440.00. Following the sale, the chairman now directly owns 79,634 shares of the company’s stock, valued at $5,695,423.68. The disclosure for this sale can be found here. Insiders sold 47,210 shares of company stock worth $3,244,934 in the last 90 days. Corporate insiders own 2.40% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of IONS. Whittier Trust Co. increased its position in shares of Ionis Pharmaceuticals by 283.0% during the second quarter. Whittier Trust Co. now owns 383 shares of the company’s stock valued at $25,000 after acquiring an additional 283 shares during the last quarter. CWM LLC increased its position in shares of Ionis Pharmaceuticals by 361.4% during the second quarter. CWM LLC now owns 406 shares of the company’s stock valued at $26,000 after acquiring an additional 318 shares during the last quarter. Ellis Investment Partners LLC purchased a new stake in shares of Ionis Pharmaceuticals during the second quarter valued at approximately $32,000. Rehmann Capital Advisory Group increased its position in shares of Ionis Pharmaceuticals by 41.3% during the second quarter. Rehmann Capital Advisory Group now owns 592 shares of the company’s stock valued at $38,000 after acquiring an additional 173 shares during the last quarter. Finally, Quadrant Capital Group LLC increased its position in shares of Ionis Pharmaceuticals by 2,839.1% during the first quarter. Quadrant Capital Group LLC now owns 676 shares of the company’s stock valued at $53,000 after acquiring an additional 653 shares during the last quarter. 90.54% of the stock is owned by institutional investors.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Featured Article: Average Daily Trade Volume – What It Means In Stock Trading

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.